{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Non+Small+Cell+Lung+Cancer",
    "query": {
      "condition": "Metastatic Non Small Cell Lung Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1490,
    "total_pages": 149,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Non+Small+Cell+Lung+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T11:58:08.259Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04068896",
      "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Head Neck Squamous Cell Carcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NGM120 30mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 30mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg Q3W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2019-10-16",
      "completion_date": "2024-01-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068896"
    },
    {
      "nct_id": "NCT04487080",
      "title": "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Amivantamab",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Lazertinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1074,
      "start_date": "2020-09-30",
      "completion_date": "2027-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 20,
      "location_summary": "Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04487080"
    },
    {
      "nct_id": "NCT00323362",
      "title": "Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2006-04",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 3,
      "location_summary": "Hamilton, New Jersey • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323362"
    },
    {
      "nct_id": "NCT00030420",
      "title": "Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2001-10",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2013-04-29",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030420"
    },
    {
      "nct_id": "NCT00407550",
      "title": "Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine HCL",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 19,
      "start_date": "2006-11",
      "completion_date": "2010-05-12",
      "has_results": true,
      "last_update_posted_date": "2019-05-02",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407550"
    },
    {
      "nct_id": "NCT04906746",
      "title": "Ruxolitinib for Cancer Cachexia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stage IV Non-small Cell Lung Cancer",
        "Cachexia"
      ],
      "interventions": [
        {
          "name": "Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tu Dan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2022-02-23",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04906746"
    },
    {
      "nct_id": "NCT03219268",
      "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Hematologic Neoplasms",
        "Ovarian Cancer",
        "HER2-positive Advanced Solid Tumors",
        "Non Small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Cholangiocarcinoma",
        "Cervical Cancer",
        "TNBC - Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tebotelimab 1 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 3 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 10 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 30 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 120 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 300 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 400 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 600 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 800 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 1200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "margetuximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2017-08-18",
      "completion_date": "2023-02-08",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 15,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219268"
    },
    {
      "nct_id": "NCT03647488",
      "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Capmatinib",
          "type": "DRUG"
        },
        {
          "name": "Spartalizumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-12-26",
      "completion_date": "2020-09-07",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 1,
      "location_summary": "Fayetteville, Arkansas",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03647488"
    },
    {
      "nct_id": "NCT00284141",
      "title": "Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Diseases",
        "Neoplasms, Lung"
      ],
      "interventions": [
        {
          "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2006-01",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2012-12-10",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00284141"
    },
    {
      "nct_id": "NCT02630186",
      "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Rociletinib",
          "type": "DRUG"
        },
        {
          "name": "MPDL3280A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clovis Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2016-02-24",
      "completion_date": "2017-09-05",
      "has_results": true,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-06-07T11:58:08.259Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02630186"
    }
  ]
}